Pfizer Inc.
AQUEOUS PHARMACEUTICAL FORMULATION COMPRISING ANTI-PD-L1 ANTIBODY AVELUMAB
Last updated:
Abstract:
The present invention relates to a novel anti-PD-L1 antibody formulation. In particular, the invention relates to an aqueous pharmaceutical formulation of the anti-PD-L1 antibody Avelumab.
Status:
Application
Type:
Utility
Filling date:
9 Dec 2020
Issue date:
8 Apr 2021